

## **REMARKS**

### **OBJECTIONS TO CLAIMS FOR INFORMALITIES**

Claims 1, 4 and 8 are objected to because of informalities.

Claim 1 has been amended to change  $R_i$  to  $R_1$ . Thus, claim 1 is submitted to be in allowable form.

Applicant respectfully submits that, in contrast to the Examiner's comment, there is no period following the phrase "compound represented" in claim 4. Thus, claim 4 is submitted to be in allowable form. If there is still some problem with claim 4, the Examiner is invited to call the Applicants' attorney Darleen J. Stockley at 202-434-1536 to resolve the issue.

Claim 8 has been amended to change  $R_i$  and  $R_z$  to  $R_1$  and  $R_2$ , respectively. Thus, claim 8 is submitted to be in allowable form.

### **CLAIM REJECTIONS UNDER 35 U.S.C. §112**

Claims 15-17 and 23 are rejected under 35 U.S.C. §112, second paragraph, as being indefinite.

For clarity, claim 15 has been amended to recite as follows:

An organic electroluminescence compound comprising:

an aryl group; and

triarylsilphenyl groups on at least one side of the aryl group, wherein the aryl group and each of the aryl groups of the triarylsilphenyl groups have two or less aromatic hydrocarbon rings.

Thus, claim 15 is now believed to be in allowable form. Since claims 16 and 17 depend from amended claim 15, claims 16-17 are submitted to be in allowable form for at least the reasons that amended claim 15 is submitted to be in allowable form.

Claim 22 has been amended to provide antecedent basis for claim 23. Thus, claim 23 is now submitted to be definite.


# **REJECTION UNDER 35 U.S.C. §102**

In the Office Action, at page 3, numbered paragraph 9, claims 15-16 were rejected under 35 U.S.C. §102(a) as being anticipated by Igarashi (USPN 6,558,819). This rejection is traversed and reconsideration is requested.


Claim 15 has been amended to recite that the triarylsilphenyl groups are on at least one side of the aryl group.

It is respectfully submitted that Igarashi does not disclose the triarylsilphenyl groups attached to at least one side of the aryl group, although Igarashi's polymer has the continuously linked repeating units represented by formula (1).


In addition, it is respectfully submitted that the Examiner's contention that Igarashi discloses a compound comprising an aryl group and triarylsilphenyl groups used in an organic electroluminescence display device as per instant claim 15 (see col. 1, lines 20-col. 2, line 36) is not quite accurate. The groups set forth by Igarashi are a repeating unit represented by formula 1:




and a repeating unit represented by formula 2:



In Igarashi,  $R^1$  and  $R^2$  each represents a substituent. Each of  $Ar^1$  and  $Ar^2$  represents an arylene linking group or a heteroarylene linking group. Each of  $R^3$  and  $R^4$  represents a hydrogen atom or a substituent. Each of  $R^5$  and  $R^6$  represents a substituent;  $m$  and  $n$  are each an integer of from 0 to 3 (apparently, there is a typographical error in the formula: the first "n" is believed to be supposed to be an "m"). Arylene groups are bivalent groups derived from arenes by removal of a hydrogen atom from two ring carbon atoms. For example, o-phenylene or benzene-1,2-diyl:



Thus, Igarashi teaches an  $\{Ar-Si-Ar\}$  repeating unit backbone, further having two substituents,  $R^1$  and  $R^2$ , attached to each Si atom, wherein the  $\{Ar-Si-Ar\}$  repeating unit backbone is further coupled to the repeating unit of formula 2



In contrast, in claim 15, the present invention does not recite repeating units, but rather recites an organic electroluminescence compound comprising: an aryl group; and triarylsilphenyl groups on at least one side of the aryl group, wherein the aryl group and each of the aryl groups of the triarylsilphenyl groups have two or less aromatic hydrocarbon rings. Claim 15 of the present invention does not recite a repeating unit of formula 2 of Igarashi.

Thus, it is respectfully submitted that claim 15 of the present invention is not anticipated under 35 U.S.C. §102(a) by Igarashi (USPN 6,558,819). Since claim 16 depends from claim 15, claim 16 is submitted not to be anticipated under 35 U.S.C. §102(a) by Igarashi (USPN 6,558,819) for at least the reasons that claim 15 is submitted not to be anticipated by same.

In the Office Action, at page 3, numbered paragraph 10, claim 22 was rejected under 35 U.S.C. §102(b) as being anticipated by Kreuder et al. (USPN 5,763,636). This rejection is traversed and reconsideration is requested.

Claim 22 has been amended to include the limitations of claim 24 and to amend "spirofluorene" to recite ---triarylsilphenyl---. Claim 24 has been cancelled without prejudice or disclaimer.

Since Kreuder does not disclose the triarylsilphenyl groups attached to at least one side of the aryl group, it is respectfully submitted that amended claim 22 distinguishes over Kreuder and also over Igarashi.

Thus, amended claim 22 is submitted to be in form for allowance under 35 U.S.C. §102(b) and is not anticipated by Kreuder et al. (USPN 5,763,636). Since claim 23 depends from amended claim 22, claim 23 is submitted to be allowable under 35 U.S.C. §102(b) and not anticipated by Kreuder et al. (USPN 5,763,636) for at least the reasons that amended claim 22 is submitted to be allowable under 35 U.S.C. §102(b) and not anticipated by Kreuder et al. (USPN 5,763,636).

#### **ALLOWED AND ALLOWABLE CLAIMS**

Claims 2-3, 5-7 and 9-10 are allowed.

The informalities in claims 1 and 8 have been corrected. Claim 4 does not appear to have the informality noted by the Examiner. Thus, claims 1, 4, and 8 are submitted to be in allowable form.

Claim 24 has been cancelled without prejudice or disclaimer. Claim 22 has been amended to include the limitations of claim 24 and to provide antecedent basis for claim 23. Thus, amended claim 22 is submitted to be in allowable form.

## CONCLUSION

In accordance with the foregoing, claim 24 has been canceled without prejudice or disclaimer, and claims 1, 8, 15, and 22 have been amended. No new matter is being presented, and approval and entry are respectfully requested.

Claims 1-10, 15-17, and 22-23 are pending and under consideration. Reconsideration is respectfully requested.

In accordance with the foregoing, it is respectfully submitted that all outstanding objections and rejections have been overcome and/or rendered moot. And further, that all pending claims patentably distinguish over the prior art. Thus, there being no further outstanding objections or rejections, the application is submitted as being in condition for allowance which action is earnestly solicited.

If the Examiner has any remaining issues to be addressed, it is believed that prosecution can be expedited by the Examiner contacting the undersigned attorney for a telephone interview to discuss resolution of such issues.

If there are any underpayments or overpayments of fees associated with the filing of this Amendment, please charge and/or credit the same to our Deposit Account No. 19-3935.

Respectfully submitted,  
STAAS & HALSEY LLP

Date:

May 3, 2004

By:

Darleen J. Stockley  
Darleen J. Stockley  
Registration No. 34,257

1201 New York Avenue, N.W. , Suite 700  
Washington, D.C. 20005  
Telephone: (202) 434-1500  
Facsimile: (202) 434-1501